CRISPR Therapeutics AG
CRSP
$57.67
-$2.33-3.88%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -22.71% | 48.96% | -53.35% | -264.49% | 56.59% |
| Total Depreciation and Amortization | 27.70% | -4.65% | -1.84% | -2.19% | 2.17% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 51.00% | -93.93% | 374.21% | 230.76% | -53.63% |
| Change in Net Operating Assets | 107.51% | 166.07% | -130.11% | 325.21% | 39.65% |
| Cash from Operations | -9.36% | 25.68% | -111.10% | -7.83% | 53.20% |
| Capital Expenditure | -598.65% | 36.75% | 43.20% | 18.90% | -15.98% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 131.65% | -269.99% | 458.56% | -118.43% | 165.73% |
| Cash from Investing | 131.20% | -270.38% | 454.22% | -118.67% | 165.49% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -60.77% | 13,042.87% | -78.67% | -37.26% | 75.06% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -60.77% | 13,042.87% | -78.67% | -37.26% | 75.06% |
| Foreign Exchange rate Adjustments | 103.70% | -133.75% | 95.12% | 147.13% | -216.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -34.26% | 323.45% | 34.10% | -186.89% | 128.05% |